Inversago Pharma

Executive Summary

Inversago Pharma is a clinical-stage biotechnology company pioneering peripherally-restricted cannabinoid receptor-1 (CB1) inverse agonists for metabolic diseases. By limiting CB1 blockade to peripheral tissues and avoiding the central nervous system, Inversago aims to circumvent the psychiatric side effects that caused the failure of prior CB1-targeting drugs. The company's lead candidate is advancing in Phase 2 trials for Prader-Willi syndrome (PWS) and obesity-related complications, addressing significant unmet needs in rare and common metabolic disorders. Backed by $95 million in funding and headquartered in Montreal, Inversago has demonstrated a strong scientific rationale and early clinical data suggesting potential efficacy with an improved safety profile. The company represents a compelling opportunity in the metabolic space, leveraging validated biology with a novel delivery approach to unlock the therapeutic potential of CB1 inverse agonism.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout in Prader-Willi syndrome60% success
• Q4 2026Initiation of Phase 2b/3 trial for obesity-related complications70% success
• TBDPotential partnership or licensing agreement for CB1 program50% success